Citius Pharmaceuticals 提交 8-K 申報，公布 2026 財年第二季度業績

false
 0001506251
 
 
 
 
 
 
 
 0001506251
 
 
 2026-05-15
 2026-05-15
 
 
 
 iso4217:USD
 
 
 xbrli:shares
 
 
 
 
 iso4217:USD
 
 
 xbrli:shares
 
 
 
 
 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of

the Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported)
May 15, 2026

 

Citius Pharmaceuticals, Inc.

(Exact name of registrant as specified in its charter)

 

Nevada

(State or other jurisdiction of incorporation)

 

 
 001-38174
  
 27-3425913

 
 (Commission File Number)
  
 (IRS Employer

Identification No.)

 
 

 
 
 11 Commerce Drive, 1st Floor,

 Cranford, NJ

  
 07016

 
 (Address of principal executive offices)
  
 (Zip Code)

 
 

Registrant's telephone number, including area code
(908) 967-6677

 

Check the appropriate box
below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following
provisions:

 

 
 ☐
 Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 
  
  

 
 ☐
 Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 
  
  

 
 ☐
 Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 
 

 
 ☐
 Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 
 

Securities registered pursuant to Section 12(b) of the Act:

 

 
 Title of each class
  
 Trading Symbol(s)
  
 Name of each exchange on which registered

 
 Common stock, $0.001 par value
  
 CTXR
  
 The Nasdaq Capital Market

 
 

Indicate by check mark whether
the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule
12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company ☐

 

If an emerging growth company,
indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial
accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

  

  

 

 

Item 2.02 Results of Operations and Financial Condition.

 

On May 15, 2026, Citius Pharmaceuticals, Inc.
issued a press release announcing its results of operations for the second quarter of fiscal 2026. A copy of the press release is furnished
as Exhibit 99.1 to this report and is incorporated herein by reference.

 

The information in this
Item 2.02 (including Exhibit 99.1) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of
1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by
reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such
a filing.

 

Item 9.01. Financial Statements and Exhibits.

 

(d) Exhibits

 

 
 Exhibit No.
  
 Description

 
 99.1
  
 Press release, dated May 15, 2026.

 
 104
  
 Cover Page Interactive Data File, formatted in Inline Extensible Business Reporting Language (iXBRL).

 

 

 1

  

 

 

SIGNATURES

 

Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.

 

 
 Date: May 15, 2026
 CITIUS PHARMACEUTICALS, INC.

 
  
  
  

 
  
 By:
 /s/ Leonard Mazur

 
  
  
 Leonard Mazur

 
  
  
 Chairman and Chief Executive Officer

 
 

 2